IART:NSD-Integra LifeSciences Holdings (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 22.13

Change

+0.12 (+0.55)%

Market Cap

USD 1.85B

Volume

0.13M

Analyst Target

USD 58.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+0.70 (+0.88%)

USD 30.74B
PODD Insulet Corporation

-0.10 (-0.04%)

USD 19.01B
MASI Masimo Corporation

+0.80 (+0.48%)

USD 9.43B
BRKR Bruker Corporation

+0.86 (+1.50%)

USD 9.04B
PRCT Procept Biorobotics Corp

+2.57 (+3.17%)

USD 4.83B
NVCR Novocure Ltd

+0.48 (+1.57%)

USD 3.61B
NARI Inari Medical Inc

+0.41 (+0.77%)

USD 3.25B
LIVN LivaNova PLC

-0.24 (-0.51%)

USD 2.83B
IRTC iRhythm Technologies Inc

+0.71 (+0.80%)

USD 2.67B
QDEL Quidel Corporation

-0.08 (-0.18%)

USD 2.57B

ETFs Containing IART

XHE SPDR® S&P Health Care Eq.. 2.34 % 0.35 %

+0.55 (+0.62%)

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.18% 32% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.18% 32% F 18% F
Trailing 12 Months  
Capital Gain -50.14% 31% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.14% 31% F 18% F
Trailing 5 Years  
Capital Gain -62.36% 51% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.36% 51% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -10.05% 28% F 21% F
Dividend Return -10.05% 28% F 20% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.23% 83% B 57% F
Risk Adjusted Return -30.25% 26% F 20% F
Market Capitalization 1.85B 88% B+ 78% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector